Pneumococcal Vaccines Market
Description
Global pneumococcal vaccines market growth is driven by factors such as rising incidence of pneumococcal diseases worldwide and growing immunization programs by various governments. Moreover, increasing awareness among people regarding pneumococcal vaccination can also drive the market growth. However, high costs associated with pneumococcal vaccines development and production can hamper the market growth. Ongoing research activities for developing affordable and effective vaccines can offer new opportunities in the near future.
Market Dynamics
Global pneumococcal vaccines market growth is primarily driven by rising prevalence of pneumococcal pneumonia, meningitis, and other serious infections caused by Streptococcus pneumoniae bacteria worldwide. As per the World Health Organization (WHO), pneumonia is one of the top five causes of death in children under age of 5 years. Moreover, increasing government funding and initiatives to promote immunization programs through national immunization schedules can drive the market growth. However, high research, development and production costs of pneumococcal vaccines can hamper the market expansion. Ongoing clinical trials assessing the safety and efficacy of new multivalent pneumococcal formulations can drive the market growth. Emerging economies present significant opportunities for market players owing to improving healthcare infrastructures in these countries.
Key features of the study
Market Dynamics
Global pneumococcal vaccines market growth is primarily driven by rising prevalence of pneumococcal pneumonia, meningitis, and other serious infections caused by Streptococcus pneumoniae bacteria worldwide. As per the World Health Organization (WHO), pneumonia is one of the top five causes of death in children under age of 5 years. Moreover, increasing government funding and initiatives to promote immunization programs through national immunization schedules can drive the market growth. However, high research, development and production costs of pneumococcal vaccines can hamper the market expansion. Ongoing clinical trials assessing the safety and efficacy of new multivalent pneumococcal formulations can drive the market growth. Emerging economies present significant opportunities for market players owing to improving healthcare infrastructures in these countries.
Key features of the study
- This report provides in-depth analysis of the global pneumococcal vaccines market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global pneumococcal vaccines market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pfizer Inc., Merck & Co., GSK plc., and Sanofi.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global pneumococcal vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- By Vaccine Type
- Pneumococcal Conjugate Vaccines (PCVs)
- PCV13 (Prevnar 13/Prevenar 13)
- PCV10 (Synflorix)
- PCV7 (Prevnar/Prevenar)
- Pneumococcal Polysaccharide Vaccines (PPVs)
- PPSV23 (Pneumovax 23)
- PPSV14 (Pneumo 14)
- By Target Population
- Adults (≥ 65 years)
- Children (< 5 years)
- High-Risk Adults (18-64 years)
- By Route of Administration
- Intramuscular
- Subcutaneous
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Merck & Co., Inc.
- GlaxoSmithKline plc (GSK)
- Sanofi
- CSL Limited
- Serum Institute of India Pvt. Ltd.
- Vaxcyte, Inc.
- Astellas Pharma Inc.
- Panacea Biotec Ltd.
- Walvax Biotechnology Co., Ltd.
- Beijing Minhai Biotechnology Co., Ltd.
- Merck KGaA
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.
- Novartis AG
- Johnson & Johnson
- Biovac
- Bharat Biotech
- Inovio Pharmaceuticals, Inc.
- Hilleman Laboratories Pvt. Ltd.
Table of Contents
150 Pages
- 1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Pneumococcal Vaccines Market, By Vaccine Type
- Global Pneumococcal Vaccines Market, By Target Population
- Global Pneumococcal Vaccines Market, By Route of Administration
- Global Pneumococcal Vaccines Market, By Distribution Channel
- Global Pneumococcal Vaccines Market, By Region
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
- 4. Global Pneumococcal Vaccines Market, By Vaccine Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pneumococcal Conjugate Vaccines (PCVs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- PCV13 (Prevnar 13/Prevenar 13)
- PCV10 (Synflorix)
- PCV7 (Prevnar/Prevenar)
- Pneumococcal Polysaccharide Vaccines (PPVs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- PPSV23 (Pneumovax 23)
- PPSV14 (Pneumo 14)
- 5. Global Pneumococcal Vaccines Market, By Target Population, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Adults (≥ 65 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Children (< 5 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- High-Risk Adults (18-64 years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 6. Global Pneumococcal Vaccines Market, By Route of Administration, 2020-2032, (USD Bn)
- Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 7. Global Pneumococcal Vaccines Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 8. Global Pneumococcal Vaccines Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021- 2032, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country/Sub-region, 2020 - 2032, (USD Bn)
- South Africa
- North Africa
- Central Africa
- 9. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc (GSK)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- CSL Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Serum Institute of India Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Vaxcyte, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Panacea Biotec Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Walvax Biotechnology Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Beijing Minhai Biotechnology Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biovac
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bharat Biotech
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Inovio Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hilleman Laboratories Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- 10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
- 11. References and Research Methodology
- References
- Research Methodology
- About us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
